Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Sathornsumetee, Sith, Rich, Jeremy N., Quinn, Jennifer A., Lagattuta, Theodore F., Egorin, Merrill J., Gururangan, Sridharan, McLendon, Roger, Herndon, James E., Friedman, Allan H., Salvado, August J., Friedman, Henry S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Duke University Press 2008
Schlagworte:
Clinical Investigations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563055/
https://ncbi.nlm.nih.gov/pubmed/18359865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge